NVO icon

Novo Nordisk

49.15 USD
+3.21
6.99%
At close Updated Nov 11, 4:00 PM EST
Pre-market
After hours
49.79
+0.64
1.3%
1 day
6.99%
5 days
4.62%
1 month
-14.52%
3 months
-1.44%
6 months
-27.44%
Year to date
-43.84%
1 year
-54.95%
5 years
45.2%
10 years
82.17%
 

About: With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Employees: 78,387

0
Funds holding %
of 7,512 funds
0
Analysts bullish %
of 4 analysts
0
Positive news %
of 185 articles
Price charts implemented using Lightweight Charts™